Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (381)	5/20/1999 2:50:00 PM
From: Vector1	Respond to of 3158

<<The INCY investors seem to be heavily into near-term earnings ->> No wonder they are disappointed. V1

To: Biomaven who wrote (381)	5/20/1999 8:14:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3158

Immunex expects that the proceeds from the offering will be used for general corporate purposes, including, but not limited to financing new product development; financing strategic acquisitions of products, product candidates, technologies or other businesses; increasing working capital required to increase sales of ENBREL; financing expansion of or constructing new manufacturing, research and office facilities; and, funding other general working capital requirements. After concluding the financing, Immunex has approximately $640 million in cash and current assets. biz.yahoo.com Gonna be a huge stampede.